Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.

ABSTRACT:

Purpose

In men with symptomatic benign prostatic hyperplasia 5α-reductase inhibitors are a main modality of treatment. More than 30% of men do not respond to the therapeutic effects of 5α-reductase inhibitors. We have found that a third of adult prostate samples do not express 5α-reductase type 2 secondary to epigenetic modifications. We evaluated whether 5α-reductase type 2 expression in benign prostatic hyperplasia specimens from symptomatic men was linked to methylation of the 5α-reductase type 2 gene promoter. We also identified associations with age, obesity, cardiac risk factors and prostate specific antigen.

Materials and methods

Prostate samples from men undergoing transurethral prostate resection were used. We determined 5α-reductase type 2 protein expression and ge

SUBMITTER: Bechis SK 

PROVIDER: S-EPMC4761873 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature